Imagine a security system for farms that not only blocks intruders but also tells you exactly who was a guest and who was a burglar. This project creates smarter vaccines for horses, sheep, and cattle that don't just prevent sickness, but leave a unique 'fingerprint'. This allows vets to tell if an animal is healthy because of the vaccine or if it is actually sick with a wild virus.
Existing vaccines for AHS, PPR, and FMD are insufficient, leaving the EU vulnerable to diseases that cause massive livestock losses. Current control methods rely heavily on culling, which is increasingly rejected by the public.
Innovative vaccines for AHS, PPR, and FMD, along with companion diagnostic tests (DIVA). A specific deliverable includes an infectious clone of FMDV O/TAI/Ban/60.
If you are a vaccine manufacturer dealing with outdated products that cannot be distinguished from wild infections — this project developed marker vaccines and companion diagnostics that allow for the differentiation of infected from vaccinated animals. This enables safer disease control without relying on mass culling.
If you are a diagnostic kit developer dealing with the need for faster, more accurate field tests for transboundary diseases — this project developed companion diagnostic tests for AHS, PPR, and FMD. These tools help prevent the spread of diseases driven by climate change and global trade.
If you are a producer dealing with the risk of highly contagious diseases like PPR, which has a case fatality rate of up to 90% — this project developed safer, more effective vaccines. This reduces the risk of total herd loss and avoids the public backlash associated with culling.
Based on available project data, specific pricing or unit costs for the vaccines are not provided.
The consortium includes 2 industry partners specifically to ensure technological readiness and market relevance, suggesting a path toward industrial scaling.
Based on available project data, specific licensing terms are not mentioned, though industry partners are involved in the development process.
The project targets diseases listed as notifiable by the World Organization for Animal Health (WOAH), aiming to provide tools that help policy makers and veterinary services reduce disease burdens.
The project period runs from 2022-07-01 to 2026-06-30, indicating that final results and validated tools will be available by mid-2026.
The project is backed by a diverse group of 13 partners across 7 countries, showing strong international cooperation. With a 15% industry ratio (2 companies) and 7 research institutes, the balance leans toward R&D, but the inclusion of industry ensures that the output is geared toward commercial viability rather than just academic curiosity.
Contact the Friedrich Loeffler Institut in Germany
Contact us to explore licensing opportunities for DIVA-capable animal vaccines.
